Where Did It Start? Subcutaneous Metastatic Melanoma

Published:September 29, 2017DOI:
      The warning signs of melanoma have been well characterized, but in some cases, those harbingers are absent. A 43-year-old white woman was admitted to our clinical department with a 2-month history of painful subcutaneous nodules. These had a hard, elastic, wooden texture and appeared on her neck, chest, abdomen, and axillary regions. With time, they became ecchymotic.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kamposioras K.
        • Pentheroudakis G.
        • Pectasides D.
        • Pavlidis N.
        Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature.
        Crit Rev Oncol Hematol. 2011; 78: 112-126
        • Saleh F.H.
        • Crotty K.A.
        • Hersey P.
        • Menzies S.W.
        Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1.
        Int J Cancer. 2001; 94: 551-557
        • Cosgarea I.
        • Ugurel S.
        • Sucker A.
        • et al.
        Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
        Oncotarget. 2017; 8: 40683-40692
        • Merkel E.A.
        • Gerami P.
        Malignant melanoma of sun-protected sites: a review of clinical, histological, and molecular features.
        Lab Invest. 2017; 97: 630-635
        • Cancer Genome Atlas Network
        Genomic classification of cutaneous melanoma.
        Cell. 2015; 161: 1681-1696
        • Chapman P.B.
        • Hauschild A.
        • Robert C.
        • et al.
        Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
        N Engl J Med. 2011; 364: 2507-2516
        • Larkin J.
        • Chiarion-Sileni V.
        • Gonzalez R.
        • et al.
        Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.
        N Engl J Med. 2015; 373: 23-34
        • Katz K.A.
        • Jonasch E.
        • Hodi F.S.
        • et al.
        Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute.
        Melanoma Res. 2005; 15: 77-82
        • Lee C.C.
        • Faries M.B.
        • Wanek L.A.
        • Morton D.L.
        Improved survival for stage IV melanoma from an unknown primary site.
        J Clin Oncol. 2009; 27: 3489-3495